Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
This invites contamination
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Research has demonstrated no significant changes in fasting glucose or insulin sensitivity in subjects using the peptide
In a supportive wellness context, carefully selected peptides may be used in very small amounts to work with the body's own biology
Drug interactions and safety
Metabolic studies of a growth hormone-releasing peptide
US$ 24.01
US$ 24.43
US$ 27.66
US$ 20.93
US$ 26.02
US$ 26.14
US$ 22.90
